Estromustine

Estromustine (developmental code name Leo 271 f), also known as estrone 17β-3-N-bis(2-chloroethyl)carbamate or estrone–cytostatic complex,[2] is a major active metabolite of the cystotatic antineoplastic agent and estrogen estramustine phosphate, a medication used in the treatment of prostate cancer.[1][3]

Not to be confused with Estramustine phosphate or Estramustine.
Estromustine
Clinical data
Other namesEoM; Leo 271 f; Estrone 17β-3-N-bis(2-chloroethyl)carbamate; Estrone–cytostatic complex
Drug classChemotherapeutic agent; Estrogen; Estrogen ester
Pharmacokinetic data
Elimination half-life14 hours[1]
Identifiers
CAS Number
PubChem CID
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H29Cl2NO3
Molar mass438.39 g·mol−1
3D model (JSmol)

See also

References
  1. Chabner BA, Longo DL (7 December 2011). Cancer Chemotherapy and Biotherapy: Principles and Practice. Lippincott Williams & Wilkins. pp. 252–. ISBN 978-1-4511-4820-6.
  2. Yamanaka H, Kitaura K, Imai K, Yuasa H, Nakai K, Matsumura Y, Uehara H, Shida K (1981). "In vivo studies of 3H-estramustine in castrated male rat". Acta Urologica Japonica. 27 (3): 243–50.
  3. Medical Subject Headings: Supplementary chemical records. The Library. 1993. p. 684.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.